Home

Articles from Altasciences

Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category.
By Altasciences · Via Business Wire · March 28, 2025
CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
Please replace the release dated November 21, 2024 with the following corrected version due to multiple revisions.
By Altasciences · Via Business Wire · November 28, 2024
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.
By Altasciences · Via Business Wire · November 13, 2024
Altasciences’ Chief Scientific Officer Named a PharmaVoice 100 Honoree
Altasciences is proud to announce that Dr. Beatrice Setnik, PhD, has been honored as a PharmaVoice 100 winner. Dr. Setnik made the list of 100 honorees for her hands-on leadership and nearly 20 years of experience in clinical drug development, with a focus on abuse potential studies. In addition to her role as Chief Scientific Officer (CSO) at Altasciences, she serves as an adjunct professor at the University of Toronto and helps develop educational programs for children in her spare time.
By Altasciences · Via Business Wire · October 9, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities
Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This marks the ninth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.
By Altasciences · Via Business Wire · May 29, 2024
Altasciences Appoints New General Manager, Clinical Operations
Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
By Altasciences · Via Business Wire · January 29, 2024
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
By Altasciences · Via Business Wire · October 31, 2023
Angel Reyes Joins Altasciences as General Manager of CDMO Services
Altasciences is pleased to welcome Angel Reyes as General Manager, Contract Development and Manufacturing Organization (CDMO) Services.
By Altasciences · Via Business Wire · October 6, 2023
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations.
By Altasciences · Via Business Wire · September 21, 2023
Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI. The trial was performed at Altasciences’ clinical facility in Montréal.
By Altasciences · Via Business Wire · August 30, 2023
Altasciences Receives 2023 CRO Leadership Award for Capabilities
Altasciences announced today that it has been recognized for excellence in contract research with a 2023 CRO Leadership Award for Capabilities. This marks the eighth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.
By Altasciences · Via Business Wire · May 9, 2023
Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s). In addition to having conducted Alzamend’s Phase IIa multiple ascending dose (MAD) clinical trial in healthy subjects, Altasciences is continuing to provide clinical monitoring, project management, biostatistics, pharmacokinetics (PK), bioanalysis, and medical writing solutions as the product candidate is evaluated in Alzheimer’s patients.
By Altasciences · Via Business Wire · April 18, 2023
Altasciences Receives Accreditation From College of American Pathologists
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Altasciences’ clinical site in Los Angeles, California, based on results of a recent on-site inspection.
By Altasciences · Via Business Wire · October 31, 2022
Altasciences Expands Laboratory Capabilities in Columbia
Altasciences’ laboratory facilities in Columbia, MO, are undergoing a significant expansion, with completion expected in 2023. The new 8,000-square-foot space will mirror Altasciences’ current bioanalytical laboratory in Laval, Québec, with state-of-the-art equipment and bioanalytical capabilities. This will supplement the service offering already available at Altasciences’ site in Seattle, WA, to support preclinical and clinical studies conducted in the U.S.
By Altasciences · Via Business Wire · October 19, 2022
Altasciences Expands Strategic Support for Early Drug Development in Europe and Adds Key Employees to Its Preclinical Team in North America
Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.
By Altasciences · Via Business Wire · October 14, 2022
Altasciences Continues Manufacturing Expansion in Philadelphia With Client‑Dedicated Building Project
Altasciences’ formulation, manufacturing, and analytical services facilities in Philadelphia, PA, are undergoing further expansion. Altasciences—an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies—is building client‑dedicated facilities for Alladapt Immunotherapeutics, Inc. (“Alladapt”), a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, with a scheduled completion time in 2023.
By Altasciences · Via Business Wire · July 15, 2022
Altasciences Receives CRO Leadership Award in Five Categories
Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
By Altasciences · Via Business Wire · May 30, 2022
Dr. Wendell P. Davis Joins Altasciences as Vice President, Pathology
Altasciences announced today the appointment of Dr. Wendell P. Davis, D.V.M., Dipl. ACVP, as Vice President, Pathology, effective February 7, 2022.
By Altasciences · Via Business Wire · February 7, 2022
Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform
Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the U.S.A.
By Altasciences · Via Business Wire · January 4, 2022
Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)
Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy. This treatment uses RespiRx™, a vibrating mesh nebulizer (VMN) with a maintenance-free disposable cartridge that reduces and potentially eliminates the risk of patient misuse and non-compliance.
By Altasciences · Via Business Wire · December 14, 2021
Altasciences Chosen by XORTX Therapeutics, Inc. to Conduct Pharmacokinetic Bridging Study XRX-OXY-101 in Support of Developing New Therapies for Progressive Kidney Disease and Acute Kidney Injury
Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
By Altasciences · Via Business Wire · December 9, 2021
Altasciences Expands Ligand Binding Laboratory to Meet High Demand for Bioanalytical Solutions
Altasciences, a leading drug development solution company, announced today the completion of a second expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services. The GLP, GCP laboratory was enlarged to include 52 benches for sample analysis, an enhanced space for cell culture and flow cytometry services, additional extraction rooms for handling all types of tissue matrices, a dedicated CL2 room for handling samples and RG2 material, a balance room for critical reagent and solution preparation, and an extraction space for an additional 50 analysts.
By Altasciences · Via Business Wire · November 23, 2021
Altasciences Continues Building Expansion with Additional Location in Philadelphia
Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients.
By Altasciences · Via Business Wire · September 27, 2021
Bruce Frank Joins Altasciences as Vice President, CDMO Operations
Altasciences announced the appointment of Dr. Bruce Frank, PhD, as Vice President, CDMO Operations. Bruce has 30 years of experience with product formulation and development, leading discovery chemistry, new technology evaluation, and project management initiatives, in both small and large biotechnology firms, making him a highly regarded leader in the CDMO space.
By Altasciences · Via Business Wire · August 13, 2021
Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
By Altasciences · Via Business Wire · May 13, 2021
Altasciences Acquires Calvert Laboratories
Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA. For more than 40 years, Calvert Laboratories has been working with clients to help develop the next generation of therapeutics aimed at extending and improving human life; in line with Altasciences’ focus on getting better drugs to the people who need them faster.
By Altasciences · Via Business Wire · May 5, 2021